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26S Abstracts June Supplement 2014Conclusions: rVAAs have signiﬁcant mortality. Open
or endovascular interventions are equally durable, but endo-
vascular interventions for rVAA result in lowermorbidity and
mortality. Aggressive treatment of pseudoaneurysms is elec-
tively recommended at diagnosis, regardless of size.
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Background: Endovascular therapy for treating com-
plex thoracoabdominal aortic dissections with aneurysmal
degeneration is riddled with challenges of inadequate false
lumen exclusion and thrombosis, inadequate proximal and
distal landing zones with septum dividing the true and false
lumen, and thepotential for visceralmalperfusion.Thismovie
presentation will focus on a stepwise approach to managing
complex thoracoabdominal dissections and aneurysms with
advanced imaging, thoracic endovascular aortic repair
(TEVAR), endovascular aneurysm repair (EVAR), in situ fen-
estrations, endovascular septectomy, and chimneys as neces-
sary adjunctive techniques for successful thoracoabdominal
dissection and aneurysm exclusion and visceral perfusion.
Technical description: Patient presented with chronic
thoracoabdominal aortic dissection from left subclavian to
iliac bifurcation with 6.5-cm thoracic aneurysm and 6-cm
abdominal aortic aneurysm (AAA). Underwent TEVAR
and false lumen coil embolization for complete false lumen
exclusion. EVAR was planned several months later. The
juxtarenal and infrarenal aorta had a chronic aortic septum
with distinct separation of true and false lumens, prohibit-
ing an adequate proximal stent graft landing zone at the
intrarenal aortic neck. True and false lumens were accessed,
and an endovascular septectomy was performed across a
fenestration at the level of the infrarenal aortic neck to
create an adequate proximal stent graft landing zone for
successful EVAR. Patient subsequently presented with jux-
tarenal 7.8 cm AAA with a true lumen pedicle perfusing all
visceral vessels. Patient underwent TEVAR bridging the
thoracic and abdominal aortic stent grafts and a chimney
to the pedicle perfusing all visceral vessels, and complete
aneurysm exclusion. At 1 year postoperatively, patient is
doing well, with complete thoracoabdominal aortic aneu-
rysms exclusion.
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Objectives: Previous studies have proven the feasibility
of performing a pancreaticoduodenectomy (Whipple) in pa-
tients with portal veinn/superior mesenteric vein (PV/
SMV) or arterial invasion. We report our institutional expe-
rience with the use of a variety of vascular reconstructive
methods during pancreatic resections for adenocarcinoma.
Methods: A retrospective review was performed iden-
tifying all Whipple and total pancreatectomy patients from
January 2003 through February 2013. All venous (PV/
SMV) and arterial (SMA/hepatic) reconstructions were
extracted and reviewed to determine survival and perioper-
ative complications.
Results: During the 10-year study period, 270 Whip-
ple and total pancreatectomy procedures were performed,
of which 183 were for adenocarcinoma of the pancreas.
A total of 60 of 183 (32.8%) vascular reconstructions
were found, 49 venous and 11 arterial. Venous reconstruc-
tion included 37 (61.7%) primary repairs, 4 (6.7%) recon-
structions with cryovein, 3 (5.0%) repairs with autologous
vein patch, 3 (5.0%) autologous saphenous reconstruc-
tions, and 2 (3.33%) portocaval shunts. Additionally, there
were 11 (18.3%) arterial reconstructions (seven hepatic ar-
tery and four superior mesenteric artery). There was one
perioperative death (1.7%). One-year survival for all recon-
structions was 70.3%, which is equivalent to T3 lesions that
did not receive vascular reconstruction (72.6%), with a me-
dian survival time of 515 days and 12 patients still alive.
Survival time was comparable with each type of venous
reconstruction, averaging 528 days (11 of 49 patients still
alive). Of the venous reconstructions, four of 49 (8.2%)
resulted in PV thrombosis, three within the primary repair
group and one delayed thrombosis within the cryovein
group. There was no thrombosis in any patients after arte-
rial reconstruction.
Conclusions: An aggressive approach for stage II
pancreatic cancers with venous or arterial invasion can be
performed with comparable results when executed by an
experienced institution with skilled oncologic and vascular
surgeons.
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